Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

NCT01442714 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

33

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy - Inability to meet the primary response endpoint

Conditions

Leukemia
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions

DRUG: Azacitidine
DRUG: Lenalidomide

Sponsor

Stanford University

Collaborators

[object Object]